ERO1B: A Potential Drug Target and Biomarker (G56605)

Target Name: ERO1B

NCBI ID: G56605

ERO1B

ERO1B: A Potential Drug Target and Biomarker

ERO1B, or Endoplasmic Reticulum Oxidoreductin-1-Like Protein B, is a protein that is expressed in various cell types throughout the body. It plays a critical role in the regulation of protein synthesis and degradation, as well as the maintenance of cellular homeostasis. In recent years, researchers have become increasingly interested in ERO1B as a potential drug target and biomarker.

ERO1B functions as a negative regulator of the nuclear translocation of the protein heat shock protein (HSP70), which is involved in the regulation of protein folding and stability. HSP70 is a protein that plays a central role in ensuring the stability of cellular proteins, and is often targeted by drugs that are designed to inhibit protein synthesis or degradation. By regulating the activity of HSP70, ERO1B helps to maintain the stability and integrity of cellular proteins, which is essential for the proper functioning of cells.

In addition to its role in regulating protein synthesis and degradation, ERO1B is also involved in the regulation of cellular signaling pathways. It has been shown to play a role in the regulation of cell adhesion, cell migration, and the development of cancer. For example, studies have shown that high levels of ERO1B are associated with the development of various types of cancer, including breast, ovarian, and prostate cancer.

ERO1B is also a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in the regulation of cellular signaling pathways makes it an attractive target for drugs that are designed to modulate these pathways. For example, studies have shown that inhibitors of ERO1B have been effective in treating various types of cancer, including breast, ovarian, and prostate cancer.

In conclusion, ERO1B is a protein that is involved in the regulation of protein synthesis and degradation, as well as the regulation of cellular signaling pathways. Its potential as a drug target and biomarker makes it an attractive target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of ERO1B in the regulation of cellular processes, and to develop effective treatments based on its properties.

Protein Name: Endoplasmic Reticulum Oxidoreductase 1 Beta

Functions: Oxidoreductase involved in disulfide bond formation in the endoplasmic reticulum. Efficiently reoxidizes P4HB/PDI, the enzyme catalyzing protein disulfide formation, in order to allow P4HB to sustain additional rounds of disulfide formation. Other protein disulfide isomerase family members can also be reoxidized, but at lower rates compared to P4HB, including PDIA2 (50% of P4HB reoxidation rate), as well as PDIA3, PDIA4, PDIA6 and NXNDC12 (<10%). Following P4HB reoxidation, passes its electrons to molecular oxygen via FAD, leading to the production of reactive oxygen species (ROS) in the cell. May be involved in oxidative proinsulin folding in pancreatic cells, hence may play a role in glucose homeostasis

The "ERO1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERO1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets